Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Financing Activities (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Cash from Financing Activities for 9 consecutive years, with -$4.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 121.72% to -$4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $72.9 million, a 46.84% increase, with the full-year FY2025 number at $72.9 million, up 46.84% from a year prior.
  • Cash from Financing Activities was -$4.8 million for Q4 2025 at Akebia Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $74.9 million in Q1 2025 to a low of -$32.9 million in Q3 2022.
  • A 5-year average of $12.3 million and a median of $1.5 million in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: plummeted 128900.0% in 2023, then soared 2346.0% in 2024.
  • Akebia Therapeutics' Cash from Financing Activities stood at $5.4 million in 2021, then tumbled by 100.02% to -$1000.0 in 2022, then tumbled by 128900.0% to -$1.3 million in 2023, then soared by 1830.62% to $22.3 million in 2024, then crashed by 121.72% to -$4.8 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Cash from Financing Activities are -$4.8 million (Q4 2025), $1.1 million (Q3 2025), and $1.7 million (Q2 2025).